Pharmacological Reports

1-Methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) is an endogenous compound with neuroprotective and antidopaminergic activities. Our previous research has shown that 1MeTIQ prevents morphine addiction and abates the expression of the reinstatement of cocaine self-administration. The current study investigated the mechanism of action of 1MeTIQ that is responsible for its considerable anticraving potential. Accordingly, we performed behavioral tests that measured the influence of 1MeTIQ on the locomotor activity of rats (Wistar) after a single cocaine (15 mg/kg, ip) dose and during cocaine sensitization (15 mg/kg, ip). In a neurochemical study, we examined the influence of 1MeTIQ on dopamine release in the rat striatum after a single cocaine administration and during cocaine sensitization using an in vivo microdialysis methodology. The data showed that 1MeTIQ (50 mg/kg, ip) only slightly inhibited cocaine-induced hyperactivity but completely antagonized the expression of locomotor cocaine sensitization. The in vivo micro-dialysis study demonstrated that the administration of 1MeTIQ before the acute cocaine injection intensified the cocaine-induced increase in dopamine release and produced a huge and long-lasting elevation of the extraneuronal concentration of dopamine (by approximately 1400%, p < 0.01) in the rat striatum. A significant increase in 3-methoxytyramine (3-MT) (by approximately 400%, p < 0.01) was also observed. During the expression of cocaine sensitization, the administration of 1MeTIQ before the reminder dose of cocaine produced an additional elevation of dopamine release but considerably more strongly increased the concentration of 3-MT in the synaptic cleft (by about 800%, p < 0.01). In light of these data and of our earlier in vitro and in vivo experiments showing a physiological role of 3-MT in the inhibitory regulation of excessive stimulation, we suggest that locomotor hyperactivity is dependent not only on dopamine concentration in the extracellular space, but also on the ratio of [DA/3-MT]. 1MeTIQ administered before the reminder dose of cocaine to cocaine-experienced rats plainly normalized the [DA/3-MT] ratio, which was increased by cocaine, and this effect may be responsible for its anti-addictive action. The results strongly support the view that 1MeTIQ may have a more general anti-abuse potential, and the extraneuronal metabolite of dopamine, 3-MT, may play a crucial role in its anti-craving effects.

Cisplatin is considered one of the most effective and commonly used chemotherapeutic drugs, but despite its high therapeutic effectiveness, most patients treated with cisplatin suffer from nausea and vomiting, neurotoxic side effects, and cerebral psychiatric disorders such as depression. Therefore, the aim of the current work was to explore whether a selective 5-HT3 receptor antagonist (Ondansetron) administered via the oral route or intranasally in microemulsion form would alleviate cisplatin’s adverse effects. The selected ondansetron microemulsion was characterized in vitro for particle size, polydispersity, zeta potential, morphology, and nasal permeation, and in vivo in terms of anti-emetic and antidepressant activity, with the assessment of biochemical markers in brain homogenates. Results revealed that both orally administered ondansetron and intranasally administered microemulsion were able to counteract the pica effect by increasing food consumption, water intake, and decreasing kaolin intake. They were also able to increase BDNF, normalize IL-6, increase serotonin, and normalize NOx, MDA, GSSH/GSH as well as 8OHdG levels in rats’ brain homogenates. The intranasal ondansetron microemulsion displayed superiority compared to oral conventional ondansetron in terms of increasing food intake, reduction of stomach content, and normalization of serotonin turnover. Ondansetron microemulsion can be administered by an alternative route of administration (intranasal) rather than oral, for patients on cisplatin chemotherapy.

During the period of mass industrial production of plastic products, the quality of human health has decreased significantly, especially in children’s neurodevelopmental disorders. Phthalates are endocrine-disrupting chemicals that can induce neurological disorders. This review aims to compile evidence concerning the associations between neurological disorders, such as attention-deficit/hyperactivity disorder, autism spectrum disorder, decreased masculine behavior, and phthalate exposure. Phthalates dysregulate the hypothalamic–pituitary–gonadal, adrenal, and thyroid axis, which is crucial for the neurodevelopmental process. Phthalates interfere with nuclear receptors in various neural structures involved in controlling brain functions and the onset of neurological disorders at the intracellular level. It is critical to increase the current knowledge concerning phthalates’ toxicity mechanism to comprehend their harmful effect on human health.

Postictal potentiation presented immediately after cortical seizures in immature rats might be due to imbalance between excitation and inhibition. The aim of the present study was to determine whether augmentation of inhibition mediated by GABAA receptors could also suppress the postictal potentiation. Twelve-day old rats with implanted electrodes were used in our study. Five drugs were tested: the agonist muscimol, the positive modulator midazolam and three neurosteroids affecting GABAA receptors—allopregnanolone, pregnanolone sulphate and pregnanolone glutamate. None of the five drugs was able to suppress potentiation appearing immediately after cortical epileptic afterdischarges, but all of them exhibited delayed anticonvulsant action 10 (in the case of midazolam and muscimol) or 20 min (all three steroids) after cortical seizures. Our results support a role of GABA in augmentation of cortical after discharges after longer intervals, whereas immediate postictal potentiation is not affected by GABAergic drugs. Due to similar effect with GABAergic drugs, the main mechanism of action of the three steroids tested is potentiation of GABAergic inhibition.

Further studies are needed to better understand the effects of potential novel antidepressants, such as cannabidiol, for the treatment of psychiatric disorders during adolescence. In this context, we evaluated in a rodent model of early-life stress (a single 24-h episode of maternal deprivation, PND 9), the antidepressant-like effects of adolescent cannabidiol alone and/or in combination with adolescent cocaine exposure (given the described beneficial effects of cannabidiol on reducing cocaine effects). Maternally deprived Sprague-Dawley male rats were treated in adolescence with cannabidiol (with or without concomitant cocaine) and exposed to a battery of behavioral tests (forced-swim, novelty-suppressed feeding, open field, sucrose preference) across time. Putative enduring molecular correlates (CB receptors, BDNF) were evaluated in the hippocampus by western blot. Cannabidiol exerted antidepressant- and anxiolytic-like effects in rats exposed to early-life stress. Cocaine did not alter affective-like behavior during adolescence in rats exposed to early-life stress; however, a depressive- and anxiogenic-like phenotype emerged during adulthood, and cannabidiol exerted some behavioral improvements, along with the growing literature supporting its beneficial role for reducing cocaine intake and/or reinstatement in rodents. Finally, cannabidiol did not modulate hippocampal CB receptors or BDNF proteins, and although the data raised interesting questions about the possible role of CB1 receptors on modulating the long-term effects of cocaine, future research is needed to expand these findings. Cannabidiol showed a promising therapeutic response in terms of ameliorating affect in a rat model of early-life stress during adolescence and up to adulthood.